Research Paper Volume 15, Issue 9 pp 3480—3497
A novel signature based on cancer-associated fibroblast genes to predict prognosis, immune feature, and therapeutic response in breast cancer
Figure 6. Verification of the predicting capability of prognostic model based on BCCGs. (A) Nomogram model build on CAF-related risk score and clinicopathological features to predict 1-, 3-, and 5-year OS of BC patients. (B) Calibration curves for the nomogram revealed qualify the predictive accuracy and ability. (C) ROC curves of the prognostic model of BC patients for 1-, 3- and 5-year. (D) The DCA of a prognostic model for 1-, 3- and 5-year overall survival, respectively.